Literature DB >> 35832993

Delayed Craniospinal Metastasis of Aggressive Nonfunctioning Pituitary Adenomas as Pituitary Carcinomas.

Ashley L B Raghu1, Megan C Everson2, Ahmed Helal2, Satoshi Kiyofuji2, Michelle J Clarke2, Michael J Link2.   

Abstract

Background  Clinical behavior of pituitary neoplasms is peculiar and notoriously difficult to predict. While aggressive tumors are common, metastasis is very rare, can be highly delayed, and there are no histological or clinical features to meaningfully predict this happening. Endocrinologically silent tumors are particularly difficult, as there is less opportunity to detect early metastasis. Together, this amounts to a situation of uncertainty over the appropriate management of such tumors before and after metastasis. Case Description  The authors report two cases of nonfunctioning aggressive pituitary adenoma (APA) each requiring two transsphenoidal surgeries, a transcranial resection and radiotherapy. Both these tumors subsequently metastasized caudally along the neuraxis, years later, as a null cell carcinoma associated with a germline CHEK2 mutation and a silent Crooke's cell carcinoma. The former represents a novel oncogenetic association. Conclusion  Delayed drop dural metastasis of pituitary carcinoma is becoming increasingly recognized. Surgical resection of the distant disease to confirm the diagnosis and relieve the mass effect, followed by temozolomide chemotherapy, is the current treatment of choice. The need for both long-term follow-up in patients with APA, and a high degree of suspicion toward dural-based radiographic findings is emphasized. Thieme. All rights reserved.

Entities:  

Keywords:  CHEK2; Crooke's cell; nonfunctioning; pituitary adenoma; pituitary carcinoma

Year:  2021        PMID: 35832993      PMCID: PMC9272318          DOI: 10.1055/s-0041-1725024

Source DB:  PubMed          Journal:  J Neurol Surg B Skull Base        ISSN: 2193-634X


  40 in total

1.  Aggressive pituitary tumours: the role of temozolomide and the assessment of MGMT status.

Authors:  Ann I McCormack; John A H Wass; Ashley B Grossman
Journal:  Eur J Clin Invest       Date:  2011-04-18       Impact factor: 4.686

Review 2.  Crooke's cell tumors of the pituitary.

Authors:  Antonio Di Ieva; Jennilee M Davidson; Luis V Syro; Fabio Rotondo; Julian F Montoya; Eva Horvath; Michael D Cusimano; Kalman Kovacs
Journal:  Neurosurgery       Date:  2015-05       Impact factor: 4.654

3.  Benign pituitary adenoma with multiple dural metastases: a case report.

Authors:  K Kumar; M Kelly
Journal:  Surg Neurol       Date:  2000-11

Review 4.  Pituitary carcinoma with intraspinal metastasis: report of two cases and review of the literature.

Authors:  Yin Qian Wang; Tao Fan; Xin Gang Zhao; Cong Liang; Xue Ling Qi; Jian Yi Li
Journal:  Int J Clin Exp Pathol       Date:  2015-08-01

5.  Successful treatment of leptomeningeally metastasised pituitary carcinoma with temozolomide.

Authors:  A van der Vlist; T J Snijders; A M E Stades; W G M Spliet; F Y F L De Vos
Journal:  Neth J Med       Date:  2017-12       Impact factor: 1.422

6.  Temozolomide therapy in patients with aggressive pituitary adenomas or carcinomas.

Authors:  Marco Losa; Fausto Bogazzi; Salvo Cannavo; Filippo Ceccato; Lorenzo Curtò; Laura De Marinis; Donato Iacovazzo; Giuseppe Lombardi; Giovanna Mantovani; Elena Mazza; Giuseppe Minniti; Maurizio Nizzoli; Michele Reni; Carla Scaroni
Journal:  J Neurooncol       Date:  2015-11-27       Impact factor: 4.130

Review 7.  Long-term survival with ACTH-secreting carcinoma of the pituitary: a case report and review of the literature.

Authors:  Rita E Landman; Melvin Horwith; Ralph E Peterson; Alexander G Khandji; Sharon L Wardlaw
Journal:  J Clin Endocrinol Metab       Date:  2002-07       Impact factor: 5.958

8.  Synchronous subarachnoid drop metastases from a pituitary adenoma with multiple recurrences. Case report.

Authors:  Norman L Lehman; Dikran S Horoupian; Griffith R Harsh
Journal:  J Neurosurg       Date:  2003-05       Impact factor: 5.115

9.  Marked Response of a Hypermutated ACTH-Secreting Pituitary Carcinoma to Ipilimumab and Nivolumab.

Authors:  Andrew L Lin; Philip Jonsson; Viviane Tabar; T Jonathan Yang; John Cuaron; Katherine Beal; Marc Cohen; Michael Postow; Marc Rosenblum; Jinru Shia; Lisa M DeAngelis; Barry S Taylor; Robert J Young; Eliza B Geer
Journal:  J Clin Endocrinol Metab       Date:  2018-10-01       Impact factor: 5.958

Review 10.  Aggressive pituitary adenomas--diagnosis and emerging treatments.

Authors:  Antonio Di Ieva; Fabio Rotondo; Luis V Syro; Michael D Cusimano; Kalman Kovacs
Journal:  Nat Rev Endocrinol       Date:  2014-05-13       Impact factor: 43.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.